Connect with us
DAPA Banner

Crypto World

Moderna (MRNA) Stock Slips Despite Beating Q4 Revenue and Earnings Estimates

Published

on

MRNA Stock Card

TLDR

  • Moderna reported Q4 revenue of $678 million, beating Wall Street estimates of $626.1 million, driven by COVID-19 vaccine sales
  • The company posted a quarterly loss of $2.11 per share, narrower than the $2.54 per share loss analysts expected
  • Moderna reiterated its 2026 revenue growth target of 10% and expects 50% of sales from U.S. markets and 50% from international
  • FDA refused to review Moderna’s flu vaccine application this week, citing trial design flaws, despite internal staff reviewers supporting the review
  • Moderna stock slipped 0.3% in premarket trading Friday despite beating earnings, after rising 36% year-to-date through Thursday

Moderna shares dipped 0.3% in premarket trading Friday even after the biotech company delivered quarterly results that topped Wall Street expectations. The mixed reaction highlights investor concerns about the company’s path forward after a rough week.

The Cambridge-based vaccine maker reported fourth-quarter revenue of $678 million. That beat analyst estimates of $626.1 million.

Full-year 2025 sales reached $1.94 billion, surpassing the $1.89 billion consensus estimate. COVID-19 vaccine sales drove the better-than-expected performance.


MRNA Stock Card
Moderna, Inc., MRNA

Moderna posted a quarterly loss of $2.11 per share. Analysts had projected a steeper loss of $2.54 per share. The latest loss was narrower than the $2.91 per share loss recorded in the same quarter last year.

CEO Stéphane Bancel said the company entered the year “with strong momentum despite the continued challenging environment in the U.S.” The company reaffirmed its expectation for 10% revenue growth in 2026 compared to 2025.

Wall Street currently expects revenue growth of about 6% for the year. Moderna forecast research and development expenses of roughly $3 billion for 2026, matching analyst estimates.

Advertisement

FDA Setback Casts Shadow

The earnings beat came days after a setback with regulators. The FDA refused Tuesday to review Moderna’s seasonal flu vaccine application.

FDA vaccine chief Vinay Prasad said the company should have compared its vaccine to standard high-dose flu shots for older adults. Moderna ran its trial using regular-dose comparisons, which the company says FDA approved 18 months ago.

Internal FDA staff reviewers had supported moving forward with the review. Prasad overruled them, according to a Wednesday report from Stat.

Moderna criticized the decision and said it was awaiting further guidance on refiling. The company has been counting on its flu vaccine and a future COVID-flu combination shot to drive future growth.

Advertisement

Looking Ahead to 2026

The company expects about 50% of 2026 sales to come from U.S. markets. International markets will account for the remaining half.

Bancel said Moderna expects to meet its 2026 targets through expansion of its next-generation COVID vaccine. Strategic partnerships in international markets will also play a role.

Shares had climbed 36% year-to-date through Thursday’s close. Positive Phase 2b trial results for an intismeran autogene vaccine used in melanoma treatment drove much of the rally.

The company continues working on newer products to offset declining COVID vaccine demand. Sales have struggled since the pandemic windfall years when demand for COVID shots collapsed.

Advertisement

Moderna’s full-year 2025 revenue of $1.94 billion came in above the $1.89 billion analyst consensus, while the company maintains its 10% revenue growth target for 2026.

Source link

Advertisement
Continue Reading
Click to comment

You must be logged in to post a comment Login

Leave a Reply

Crypto World

Crypto selloff deepens with $400 million liquidations and rising short interest

Published

on

Crypto selloff deepens with $400 million liquidations and rising short interest

Bitcoin gave back a large portion of its recent gains on Thursday, now trading at $66,700 having lost 2.4% of its value since midnight UTC.

Ether (ETH) performed even worse, tumbling by 4.4% as the broader crypto market struggles to deal with continued risk-off sentiment.

The latest plunge was spurred by U.S. president Donald Trump, who said on Wednesday evening that the war in Iran would continue with extensive strikes on Iran.

“Over the next two to three weeks, we’re going to bring them back to the stone ages where they belong,” he said.

Advertisement

The comments led to an immediate spike in oil prices, with brent crude rising by around 10% to $108 per barrel as U.S. equities diverged.

Nasdaq 100 and S&P 500 futures lost 1.5% and 1.1% respectively while the U.S. dollar increased by 0.5% to above 100 points.

Derivatives positioning

  • BTC’s price has dropped over 2% since midnight UTC hours alongside a slightly uptick in open interest in major USD- and USDT-denominated futures. Plus, perpetual funding rates have dropped to their most negative since March 12. This combination suggests that traders are bearish and shorting the falling market.
  • In ether’s case, funding rates are most negative since October last year, a sign of strong bias for bearish bets. Meanwhile, bearishness in solana (SOL) is surprisingly more measured despite the overnight hack.
  • Privacy-focused zcash (ZEC) and have seen a notable decline in open interest (OI) in 24 hours, a sign of capital outflows.
  • Nearly $400 million in futures positions have been liquidated due to margin shortfalls. That’s a 17% increase in losses compared to the previous day.
  • Despite renewed risk-off tone, bitcoin and ether’s 30-day implied volatility indices remain flat in recent ranges. It points to orderly selling in the spot market rather than panic.
  • There is little scope for panic because traders are already positioned for market swoon. They have been consistently chasing bitcoin and ether put options (downside hedges) since the start of the year. As of writing, bitcoin and ether puts remained pricier than calls across all tenors on Deribit.
  • Block flows featured demand for ether straddles, a volatility strategy, and put spreads and bitcoin call spreads.

Token talk

  • The worst performing benchmark on Thursday was CoinDesk’s DeFi Select Index (DFX), which lost 5.9% since midnight UTC, closely followed by the CoinDesk Computing Select Index (CPUS) that tumbled by 5%.
  • Ethena (ENA) led the downside move as it fell by more than 10% on Thursday, there was also a heavy drawdown among DeFi tokens UNI, LDO, SKY and AAVE – all shedding between 4.2% and 6.5% during Asian and European hours on Thursday.
  • Algorand (ALGO) bucked the bearish market trend, rising by around 0.8% on Thursday as it continues its rich vein of form having rallied by 22% in the past week.
  • CoinMarketCap’s “altcoin season” index is down from 50/100 to 42/100 since March 30, highlighting relative weakness across the sector.

Source link

Continue Reading

Crypto World

CLARITY Act Nearing Senate Markup, Floor Vote

Published

on

CLARITY Act Nearing Senate Markup, Floor Vote

Coinbase chief legal officer Paul Grewal said the US Digital Asset Market Clarity Act is “moving toward” a markup hearing in the US Senate Banking Committee and could eventually move to a floor vote if senators resolve the stablecoin yield dispute and schedule a markup.

Speaking in a Wednesday interview on Fox Business, Grewal said lawmakers are nearing agreement on core elements of the crypto market structure bill, even as debate continues over stablecoin yield. “I think we’re very close to a deal,” he said.

The remarks point to possible movement on one of the last major sticking points in Senate talks over crypto market structure legislation: whether stablecoin issuers or platforms should be allowed to offer yield or similar rewards. The dispute has helped delay a Senate Banking Committee markup, leaving the broader effort to set federal rules for digital asset oversight still unresolved.

US banks have pushed for restrictions, arguing that such incentives could draw deposits away from traditional institutions and disrupt the banking system. Grewal pushed back on that claim, saying there is no evidence to support fears of deposit flight.

Advertisement

The US House of Representatives passed the CLARITY Act on July 17, 2025. In January, Senate Banking Committee Chair Tim Scott delayed a planned markup, which has yet to be rescheduled.

Related: Crypto investor sentiment will rise once CLARITY Act is passed: Bessent

Trump blames banks for stalling crypto bill

Last month, US President Donald Trump accused banks of undermining efforts to pass crypto market structure legislation, saying they are blocking progress over disagreements on stablecoin yield payments. “The Banks should not be trying to undercut The Genius Act, or hold The Clarity Act hostage,” he wrote.

It was later reported that Trump met privately with Coinbase CEO Brian Armstrong just hours before issuing the statement.

Advertisement
Coinbase shares are down 23% YTD. Source: Yahoo! Finance

In January, Armstrong said Coinbase could not back the market structure bill “as written,” pointing to draft amendments that would eliminate stablecoin rewards and let banks restrict competition.

Related: CLARITY Act 2026 odds ‘extremely low’ if not passed before April: Exec

CLARITY delay could expose crypto to crackdowns

Last week, Coin Center executive director Peter Van Valkenburgh warned that failure to pass the CLARITY Act could leave the crypto industry vulnerable to a future US administration taking a tougher stance. He argued that rejecting developer protections in favor of short-term business interests risks creating a system shaped by political shifts rather than clear law.

“The point of passing CLARITY is not to trust this administration. It is to bind the next one,” he said.

Magazine: Bitcoin may take 7 years to upgrade to post-quantum — BIP-360 co-author

Advertisement